Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
21 pending office actions • 16 art units • 20 examiners • 0 of 21 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
The Medical College of Wisconsin Inc. has 21 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. These 21 actions are being reviewed by 20 distinct examiners, which shows that nearly every pending application is being handled by a different official. This ratio of 20 distinct examiners to the pending actions suggests a decentralized prosecution environment where individual examiner discretion is paramount.
The company's patent applications are spread across 16 distinct art units, indicating a broad administrative footprint within the patent office. With the pending office actions distributed among 16 distinct art units, the portfolio is subject to the varied rules and trends of many different examination groups. This diversity requires a prosecution strategy that can effectively address the specific requirements of the technical units.
HANEY, AMANDA MARIE is the busiest examiner for this portfolio, currently managing 2 pending office actions. This represents the highest level of examiner concentration, yet it only accounts for 2 of the total pending actions. The presence of the examiners across the art units highlights the need for a flexible approach to navigate the many different perspectives involved in the company's prosecution.
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 3 (14%) |
| §101 + other | 5 (24%) |
| §103 only | 3 (14%) |
| §102 only | 1 (5%) |
| §112 only | 3 (14%) |
| Multi-statute (no §101) | 6 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HANEY, AMANDA MARIE | 2 | 36.4% | +44.9% |
| LANNU, JOSHUA DARYL DEANON | 1 | 82.1% | +24.2% |
| NASSER, ROBERT L | 1 | 72.9% | +11.2% |
| ABUZEINEH, HANAN ISAM | 1 | 53.2% | +54.3% |
| NGUYEN, HENRY H | 1 | 63.7% | +37.2% |
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
| BUCHANAN, BAILEY CHEYENNE | 1 | 42.9% | +57.1% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17493230 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 141d overdue |
| 17427005 | Systems and Methods for Sound Mapping of Anatomical and Physiological Acoustic Sources Using an Array of Acoustic Sensors | PORTILLO, JAIRO H | 88d overdue |
| 19288971 | MONITORING ORGAN MORPHOLOGY FOR RADIATION TREATMENT DELIVERY USING ULTRASOUND | LANNU, JOSHUA DARYL DEANON | 12d |
| 19128963 | ELECTROMAGNETIC COLPOTOMY CUP SYSTEM | NASSER, ROBERT L | — |
| 18717658 | Indicator Clearance Monitoring in Machine Perfusion of an Organ | ABUZEINEH, HANAN ISAM | — |
| 18497541 | METHODS FOR ASSESSING CELLULAR OR TISSUE INJURY USING MITOCHONDRIAL AND/OR NUCLEAR CELL-FREE DNA | NGUYEN, HENRY H | — |
| 18546143 | Small Molecule Inhibitors of PBRM1-BD2 | PECKHAM, RICHARD GRANT | — |
| 18343097 | ASSESSING TRANSPLANT COMPLICATION RISK WITH TOTAL CELL-FREE DNA | BUCHANAN, BAILEY CHEYENNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17493230 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 141d overdue |
| 19288971 | MONITORING ORGAN MORPHOLOGY FOR RADIATION TREATMENT DELIVERY USING ULTRASOUND | LANNU, JOSHUA DARYL DEANON | 12d |
| 18252073 | Peptide Inhibitors of Human Mitochondrial Fission Protein 1 and Methods of Use | REYNOLDS, FRED H | 14d |
| 16623725 | TRANSPLANT PATIENT MONITORING WITH CELL-FREE DNA | HANEY, AMANDA MARIE | 27d |
| 18287632 | Quinazoline Derivatives, Pharmaceutical Compositions, and Therapeutic Uses Related to Nox Inhibition | BELL, SARA ELIZABETH | 79d |
| 19128963 | ELECTROMAGNETIC COLPOTOMY CUP SYSTEM | NASSER, ROBERT L | — |
| 18717658 | Indicator Clearance Monitoring in Machine Perfusion of an Organ | ABUZEINEH, HANAN ISAM | — |
| 18497541 | METHODS FOR ASSESSING CELLULAR OR TISSUE INJURY USING MITOCHONDRIAL AND/OR NUCLEAR CELL-FREE DNA | NGUYEN, HENRY H | — |
| Art Unit | Apps |
|---|---|
| 1682 | 3 |
| 3791 | 2 |
| 1685 | 2 |
| 3992 | 1 |
| 1758 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| 1644 | 1 |
| 1658 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19288971 | MONITORING ORGAN MORPHOLOGY FOR RADIATION TREATMENT DELIVERY USING ULTRASOUND | LANNU, JOSHUA DARYL DEANON | 3791 | §103§112 | Non-Final OA | 12d | Pending | Aug 01, 2025 |
| 19128963 | ELECTROMAGNETIC COLPOTOMY CUP SYSTEM | NASSER, ROBERT L | 3992 | §102§103 | Non-Final OA | — | Pending | May 09, 2025 |
| 18717658 | Indicator Clearance Monitoring in Machine Perfusion of an Organ | ABUZEINEH, HANAN ISAM | — | §102§103 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18497541 | METHODS FOR ASSESSING CELLULAR OR TISSUE INJURY USING MITOCHONDRIAL AND/OR NUCLEAR CELL-FREE DNA | NGUYEN, HENRY H | 1758 | §101§102§103§112DP | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18287632 | Quinazoline Derivatives, Pharmaceutical Compositions, and Therapeutic Uses Related to Nox Inhibition | BELL, SARA ELIZABETH | 1625 | §112 | Non-Final OA | 79d | Pending | Oct 19, 2023 |
| 18546143 | Small Molecule Inhibitors of PBRM1-BD2 | PECKHAM, RICHARD GRANT | 1627 | §102§112 | Final Rejection | — | Pending | Aug 11, 2023 |
| 18343097 | ASSESSING TRANSPLANT COMPLICATION RISK WITH TOTAL CELL-FREE DNA | BUCHANAN, BAILEY CHEYENNE | 1682 | §101§103Other | Final Rejection | — | Pending | Jun 28, 2023 |
| 18326373 | METHODS FOR TREATING HEMATOLOGIC CANCERS | OUSPENSKI, ILIA I | 1644 | §112Other | Non-Final OA | — | Pending | May 31, 2023 |
| 18252073 | Peptide Inhibitors of Human Mitochondrial Fission Protein 1 and Methods of Use | REYNOLDS, FRED H | 1658 | §112 | Non-Final OA | 14d | Pending | May 08, 2023 |
| 18035921 | ASSESSING RISK WITH PRE-OPERATIVE TOTAL CELL-FREE DNA | KALLAL, ROBERT JAMES | 1685 | §101§102§103§112 | Non-Final OA | — | Pending | May 08, 2023 |
| 18005802 | Multiple Myeloma Mapping and Uses Thereof | DENT, ALANA HARRIS | 1643 | §102§103§112 | Non-Final OA | — | Pending | Jan 17, 2023 |
| 18057494 | COMPOSITIONS AND METHODS FOR REDUCING CELL-FREE DNA | SMITH, PETER DANIEL | 3781 | §103 | Non-Final OA | 28d overdue | Pending | Nov 21, 2022 |
| 17965148 | Assay to Differentiate Natural CMV Infection from CMV Vaccines that Lack UL144 | BLUMEL, BENJAMIN P | 1671 | §102§103§112 | Final Rejection | — | Pending | Oct 13, 2022 |
| 17911022 | 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators | BURKETT, DANIEL JOHN | 1624 | §102 | Non-Final OA | 46d overdue | Pending | Sep 12, 2022 |
| 17817561 | TRAUMA-INTERVENTION DETERMINATION | KHATTAR, RAJESH | 3684 | §101 | Final Rejection | — | Pending | Aug 04, 2022 |
| 17493293 | TRANSPLANT PATIENT MONITORING WITH CELL-FREE DNA | RYAN, DOUGLAS CHARLES | 1635 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 04, 2021 |
| 17493230 | ASSESSING CONDITIONS IN TRANSPLANT SUBJECTS USING DONOR-SPECIFIC CELL-FREE DNA | HANEY, AMANDA MARIE | 1682 | §101§103§112DP | Final Rejection | 141d overdue | Pending | Oct 04, 2021 |
| 17442968 | Tip60 Inhibitors and Methods of Use for Cardiovascular Disease | BARSKY, JARED | 1628 | §103 | Non-Final OA | 15d | Pending | Sep 24, 2021 |
| 17427005 | Systems and Methods for Sound Mapping of Anatomical and Physiological Acoustic Sources Using an Array of Acoustic Sensors | PORTILLO, JAIRO H | 3791 | §101 | Non-Final OA | 88d overdue | Pending | Jul 29, 2021 |
| 16623725 | TRANSPLANT PATIENT MONITORING WITH CELL-FREE DNA | HANEY, AMANDA MARIE | 1682 | §103 | Final Rejection | 27d | Pending | Dec 17, 2019 |
| 16666210 | HIGHLY SENSITIVE TRANSPLANT REJECTION SURVEILLANCE USING TARGETED DETECTION OF DONOR SPECIFIC CELL FREE DNA | MINCHELLA, KAITLYN L | 1685 | §101Other | Non-Final OA | — | Pending | Oct 28, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial